Article ; Online: Efficacy of mycophenolate mofetil in sarcoidosis.
2014 Volume 108, Issue 11, Page(s) 1663–1669
Abstract: ... of this retrospective study was to examine the role of mycophenolate mofetil (MMF) as an alternative therapy in the treatment ... studies investigating the efficacy of MMF as the initial steroid-sparing agent are needed to further ... Background: Immunosuppressive (IS) therapy is indicated to treat progressive sarcoidosis ...
| Abstract | Background: Immunosuppressive (IS) therapy is indicated to treat progressive sarcoidosis, but randomized controlled trials to guide physicians in the use of steroid sparing agents are lacking. The aim of this retrospective study was to examine the role of mycophenolate mofetil (MMF) as an alternative therapy in the treatment of sarcoidosis. Methods: A retrospective chart review of all patients who had been prescribed MMF between January 2008 and October 2011 was conducted. Patients with insufficient data or who had another IS therapy initiated concomitantly with MMF, including prednisone, were excluded. Physiological data obtained at the time MMF therapy was initiated as well as six and twelve months before and after therapy was extracted. Longitudinal analyses of the effect of MMF on changes in pulmonary function at MMF start, 6 months, 12 months pre and post MMF therapy were conducted. Results: 37/76 patients met our inclusion/exclusion criteria. There were no statistically significant changes in PFT measurements pre and post MMF therapy. We did find a trend (p = 0.07) towards improvement in DLCO 12 months pre and post MMF in patients who were started on MMF due to intolerance to previous IS therapy compared to those who were unresponsive to their previous IS therapy. We also noted a reduction in prednisone dose in those treated with MMF. Conclusion: MMF appears to offer no extra benefit to sarcoidosis patients unresponsive to previous steroid-sparing agents, but may be beneficial in patients intolerant to their previous steroid-sparing agent. Additional studies investigating the efficacy of MMF as the initial steroid-sparing agent are needed to further clarify the role of MMF in sarcoidosis. |
|---|---|
| MeSH term(s) | Adult ; Aged ; Drug Administration Schedule ; Drug Evaluation/methods ; Drug Therapy, Combination ; Female ; Glucocorticoids/administration & dosage ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Middle Aged ; Mycophenolic Acid/analogs & derivatives ; Mycophenolic Acid/therapeutic use ; Prednisone/administration & dosage ; Pulmonary Diffusing Capacity/drug effects ; Retrospective Studies ; Sarcoidosis, Pulmonary/drug therapy ; Sarcoidosis, Pulmonary/physiopathology ; Treatment Outcome ; Vital Capacity/drug effects |
| Chemical Substances | Glucocorticoids ; Immunosuppressive Agents ; Mycophenolic Acid (HU9DX48N0T) ; Prednisone (VB0R961HZT) |
| Language | English |
| Publishing date | 2014-09-28 |
| Publishing country | England |
| Document type | Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 1003348-8 |
| ISSN | 1532-3064 ; 0954-6111 |
| ISSN (online) | 1532-3064 |
| ISSN | 0954-6111 |
| DOI | 10.1016/j.rmed.2014.09.013 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Ui III Zs.19: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.